Abstract INTRODUCTION At present, no disease-modifying osteoarthritis drugs (DMOADS) are approved by the FDA (US Food and Drug Administration); possibly partly due to inadequate trial design since efficacy demonstration requires disease progression in the placebo group. We investigated whether combinations of biochemical and magnetic resonance imaging (MRI)-based markers provided effective diagnostic and prognostic tools for […]
Identification of progressors in osteoarthritis by combining biochemical and MRI-based markers.
January 1, 2009
Arthritis Res Ther